A recent pre-clinical study showed that supplement Nicotinamide Riboside “NR” (FAQs) (Reviews) reduced hearing loss in mice. The lead scientist on the study commented:

“These findings are potentially meaningful for those with Cockayne syndrome as well as the broader aging population who experience hearing loss,” commented Dr. Vilhelm A. Bohr, Senior Investigator, NIH National Institute on Aging, and study principal investigator.  “The next step is to move this animal model research into a human trial.”

Previous Pre-Clinical Studies:

Previous pre-clinical studies showed NAD depletion plays an important role in the cause of age related hearing loss.

Chromadex Conclusion (from PR):

“These results reinforce findings from earlier preclinicals which suggested NR may help in delaying or reducing age-related hearing loss (ARHL), though further studies are required to confirm these findings in humans”

Related:

  • Latest Pre-Clinical Trial Hearing Results HERE.
  • Previous Pre-Clinical Trial Hearing Results HERE.
  • Chromadex (NR and TRU Niagen) press release HERE.
  • Nicotinamide Riboside “NR” (FAQs) (Life Changing Anecdotes)

FOLLOW us on Twitter @RaisingNAD